Clinical Trial Update: A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis [Phase 1, Phase 2]

View source ↗

Summary

The FT-4101 trial in overweight or obese participants with nonalcoholic steatohepatitis (NASH) was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis
• Obesity

Drugs mentioned

• FT-4101

Snippet

Sponsor: Forma Therapeutics, Inc. | Conditions: Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-21